Abstract:Histologic variants of prostate carcinoma account for 5–10% of the disease and are typically seen in association with conventional acinar carcinoma. These variants often differ from the latter in clinical, immunophenotypic, and biologic potential. Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas. However, the frequency and significance of this critical molecular event is unknown in the histologic variants of prostate carcinoma. Here, we used break-apart fluorescence in situ hybridization to assess TMPRSS2 and ETS aberrations in a series of select histologic variants: foamy gland carcinoma ( N =17), ductal adenocarcinoma ( N =18), mucinous carcinoma ( N =18), and small cell carcinoma ( N =7). A histologic variation of acinar adenocarcinoma, demonstrating glomeruloid morphology ( N =9), was also investigated. Overall, 55% of histologic variant or variation morphologies demonstrated ETS aberrations ( ERG in 54% and ETV1 in 1%). TMPRSS2:ERG fusion was identified in 83% (15/18), 71% (5/7), 50% (9/18), 33% (3/9), and 29% (5/17) of mucinous, small cell, ductal, glomeruloid, and foamy gland prostate carcinomas, respectively. Previously, we reported that 100% of androgen-independent metastatic prostate carcinomas harboring TMPRSS2:ERG gene fusion were associated with interstitial deletion (Edel). Interestingly, ERG rearrangement in small cell carcinomas occurred exclusively through Edel, supporting the notion that TMPRSS2:ERG with Edel is an aggressive molecular subtype. SPINK1, a biomarker expressed exclusively in a subset of ETS negative prostate carcinomas, was expressed in 6% of ETS negative histologic variants, specifically in ductal adenocarcinoma. Notably, 88% (43/49) variant morphologies in this cohort showed concordance of TMPRSS2:ERG fusion with associated conventional acinar type, suggesting that variant morphology is clonally related to the latter. Overall, our data provide insight into the origin, molecular mechanism, and phenotypic association of ETS fusions in histologic variants of prostate carcinoma.

Supplementary Table 2 from Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer

Supplementary Figures 1-2, Tables 1-8 from Distinct Genomic Alterations in Prostate Cancers in Chinese and Western Populations Suggest Alternative Pathways of Prostate Carcinogenesis

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

Supplementary Table S1 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer

Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Supplementary Information from &Lt;i>tmprss2-Erg</i> Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in <i>pten</i> and &Lt;i>tp53</i>-Mutated Prostate Cancer

Heterogeneity Of Tmprss2 Gene Rearrangements In Multifocal Prostate Adenocarcinoma: Molecular Evidence For An Independent Group Of Diseases

Supplementary Methods and Data (posted 7/5/2011) from Characterization of <i>KRAS</i> Rearrangements in Metastatic Prostate Cancer

Comprehensive Assessment of TMPRSS2 and ETS Family Molecular Aberrations in Histologic Variants of Prostate Carcinoma

Supplemental Table 1 from RB Loss Promotes Prostate Cancer Metastasis

Supplementary Table 1 from Metastatic Prostate Cancers with BRCA2 Versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Ets Rearrangements and Prostate Cancer Initiation

Supplementary Table 1, Figures 1-3 from A Fluorescence in Situ Hybridization Screen for E26 Transformation–Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer

Supplementary Table 1 from P300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis

Supplementary Table 2 from Androgen Deprivation Causes Epithelial–Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy

Supplementary Table 4 from Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer

Supplementary Table 1 from Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma

Supplementary Table from Functional Analysis of MET Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination

Supplementary Data from Transcriptional Regulation of CXCR4 in Prostate Cancer: Significance of TMPRSS2-ERG Fusions

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes